Endocrine Abstracts

Introduction: Non-alcoholic fatty liver disease (NAFLD), defined as excess fat accumulation in the liver, is increasingly prevalent due to obesity. NAFLD may lead to steatohepatitis and eventually cirrhosis. Weight loss, either through diet and exercise or medications such as the glucagon-like peptide-1 agonist liraglutide, improves transaminitis, a marker of NAFLD severity. Visceral obesity is associated with increased plasma levels of the amino acids alanine, phenylalanine, ...